Inflammation, oxidative stress and renin angiotensin system in atherosclerosis
- PMID: 26322175
- PMCID: PMC4549761
- DOI: 10.4331/wjbc.v6.i3.209
Inflammation, oxidative stress and renin angiotensin system in atherosclerosis
Abstract
Atherosclerosis is a chronic inflammatory disease associated with cardiovascular dysfunction including myocardial infarction, unstable angina, sudden cardiac death, stroke and peripheral thromboses. It has been predicted that atherosclerosis will be the primary cause of death in the world by 2020. Atherogenesis is initiated by endothelial injury due to oxidative stress associated with cardiovascular risk factors including diabetes mellitus, hypertension, cigarette smoking, dyslipidemia, obesity, and metabolic syndrome. The impairment of the endothelium associated with cardiovascular risk factors creates an imbalance between vasodilating and vasoconstricting factors, in particular, an increase in angiotensin II (Ang II) and a decrease in nitric oxide. The renin-angiotensin system (RAS), and its primary mediator Ang II, also have a direct influence on the progression of the atherosclerotic process via effects on endothelial function, inflammation, fibrinolytic balance, and plaque stability. Anti-inflammatory agents [statins, secretory phospholipase A2 inhibitor, lipoprotein-associated phospholipase A2 inhibitor, 5-lipoxygenase activating protein, chemokine motif ligand-2, C-C chemokine motif receptor 2 pathway inhibitors, methotrexate, IL-1 pathway inhibitor and RAS inhibitors (angiotensin-converting enzyme inhibitors)], Ang II receptor blockers and ranin inhibitors may slow inflammatory processes and disease progression. Several studies in human using anti-inflammatory agents and RAS inhibitors revealed vascular benefits and reduced progression of coronary atherosclerosis in patients with stable angina pectoris; decreased vascular inflammatory markers, improved common carotid intima-media thickness and plaque volume in patients with diagnosed atherosclerosis. Recent preclinical studies have demonstrated therapeutic efficacy of vitamin D analogs paricalcitol in ApoE-deficient atherosclerotic mice.
Keywords: Anti-inflammatory drugs; Atherosclerosis; Inflammation; Oxidants/antioxidants imbalance; Renin-angiotensin system; Renin-angiotensin system blockers.
Figures
Similar articles
-
Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.Vasc Health Risk Manag. 2011;7:405-16. doi: 10.2147/VHRM.S20737. Epub 2011 Jun 24. Vasc Health Risk Manag. 2011. PMID: 21796255 Free PMC article. Review.
-
The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?Vasc Health Risk Manag. 2008;4(3):597-604. doi: 10.2147/vhrm.s2008. Vasc Health Risk Manag. 2008. PMID: 18827909 Free PMC article. Review.
-
[Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in metabolic disorders: hypercholesterolaemia and diabetes].Drugs. 2002;62 Spec No 1:31-41. Drugs. 2002. PMID: 12036387 Review. French.
-
ACE inhibitors and angiotensin II receptor antagonists.Handb Exp Pharmacol. 2005;(170):407-42. doi: 10.1007/3-540-27661-0_15. Handb Exp Pharmacol. 2005. PMID: 16596809 Review.
-
Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease.Am J Cardiol. 2006 Jul 1;98(1):121-8. doi: 10.1016/j.amjcard.2006.01.059. Epub 2006 May 9. Am J Cardiol. 2006. PMID: 16784934 Review.
Cited by
-
Increased Oxidative Stress and Decreased Sirtuin-3 and FOXO3 Expression Following Carotid Artery Intimal Injury in Hyperlipidemic Yucatan Microswine.Cardiol Cardiovasc Med. 2024;8(1):33-42. doi: 10.26502/fccm.92920355. Epub 2024 Jan 22. Cardiol Cardiovasc Med. 2024. PMID: 38333571 Free PMC article.
-
Losartan suppresses the inflammatory response in collagen-induced arthritis by inhibiting the MAPK and NF-κB pathways in B and T cells.Inflammopharmacology. 2019 Jun;27(3):487-502. doi: 10.1007/s10787-018-0545-2. Epub 2018 Nov 13. Inflammopharmacology. 2019. PMID: 30426454
-
Possible role of LCZ696 in atherosclerosis: new inroads and perspective.Mol Cell Biochem. 2024 Aug;479(8):1895-1908. doi: 10.1007/s11010-023-04816-x. Epub 2023 Aug 1. Mol Cell Biochem. 2024. PMID: 37526794 Review.
-
New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease.Clin Sci (Lond). 2019 Apr 12;133(7):885-904. doi: 10.1042/CS20180316. Print 2019 Apr 15. Clin Sci (Lond). 2019. PMID: 30979844 Free PMC article. Review.
-
Relationship between neutrophil/lymphocyte ratio and epicardial fat tissue thickness in patients with newly diagnosed hypertension.J Int Med Res. 2018 Mar;46(3):940-950. doi: 10.1177/0300060517749130. Epub 2018 Jan 14. J Int Med Res. 2018. PMID: 29332485 Free PMC article.
References
-
- Scott J. The pathogenesis of atherosclerosis and new opportunities for treatment and prevention. J Neural Transm Suppl. 2002;(63):1–17. - PubMed
-
- Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74:213–220. - PubMed
-
- Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913–919. - PubMed
-
- Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous